Importantly, the ratios of Treg cells to CD44+ CD8+ T cells both in the dLNs and tumor-infiltrating lymphocytes were remarkably reduced in the combination treatment group (Fig. 5E). The gene discussed is CD8A; the disease is neoplasm.